The Effect of Semaglutide on Bone Health
NCT07165158 on ClinicalTrials.gov · last registry update 2025-09-17
An unusually large phase 4: 150 participants, more than double the 72 typical for the stage. Due to report 31 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: lumbar bone mineral density. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Sponsor type
- Other
- Enrollment
- 150
- Started
- 2025-09-15
- Primary completion
- 2026-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
lumbar bone mineral density
Conditions studied
Osteoporosis · Osteoporosis Fracture · T2DM
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.